News
SBFM
2.750
-3.51%
-0.100
Weekly Report: what happened at SBFM last week (1102-1106)?
Weekly Report · 2d ago
Weekly Report: what happened at SBFM last week (1026-1030)?
Weekly Report · 11/02 09:08
Sunshine Biopharma Consensus Price Target Raised 1,900% to $1,142.40
NASDAQ · 11/02 01:21
Weekly Report: what happened at SBFM last week (1019-1023)?
Weekly Report · 10/26 09:08
Sunshine Biopharma Inc trading halted, news pending
TipRanks · 10/23 23:50
Sunshine Biopharma announces reverse stock split
TipRanks · 10/22 13:25
Sunshine Biopharma announces reverse stock split to maintain Nasdaq listing
Seeking Alpha · 10/22 13:25
Weekly Report: what happened at SBFM last week (1012-1016)?
Weekly Report · 10/19 09:08
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/15 17:05
Sunshine Biopharma Approves Dilutive Share Issuance Plan
TipRanks · 10/14 20:30
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/13 17:06
Weekly Report: what happened at SBFM last week (1005-1009)?
Weekly Report · 10/12 09:09
Sunshine Biopharma Completes $6 Million Public Offering
TipRanks · 10/09 21:49
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 10/09 17:05
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
Barchart · 10/09 10:17
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 10/08 17:05
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
Benzinga · 10/08 16:03
Dow Falls Over 100 Points; US Initial Jobless Claims Decline
Benzinga · 10/08 13:39
Sunshine Biopharma prices $6.0M public offering
TipRanks · 10/08 12:35
Sunshine Biopharma announces pricing of $6M public offering
Seeking Alpha · 10/08 12:17
More
Webull provides a variety of real-time SBFM stock news. You can receive the latest news about Sunshine Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About SBFM
Sunshine Biopharma Inc. is a pharmaceutical company engaged in offering and researching life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has approximately 70 generic prescription drugs on the market in Canada. In addition, the Company is conducting a proprietary drug development program which is comprised of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for the treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The Company operates two wholly owned subsidiaries: Nora Pharma Inc., which has a portfolio of pharmaceutical products consisting of various prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells nonprescription over-the-counter (OTC) products.